MarketCap
Facebook
X
Telegram
Athira Pharma EBITDA | ATHA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Athira Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -101 M | -99.9 M | -124 M | -103 M | -63.5 M | -18.7 M | -4.74 M | -5.09 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.74 M | -124 M | -65.1 M |
Quarterly EBITDA Athira Pharma
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17 M | -6.67 M | -7.09 M | -9.29 M | - | -29.4 M | -27.8 M | -27.4 M | - | -34.8 M | -31.4 M | -29.5 M | - | -23.9 M | -23.3 M | -23.2 M | - | -17.7 M | -16.5 M | -10.7 M | - | -7.4 M | -2.25 M | -1.27 M | - | -1.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.27 M | -34.8 M | -17.4 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M |  USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.8 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-137 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-29.2 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-270 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-135 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
-3.99 M | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
-33.1 M | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
-199 M | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
121 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
489 M | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
-284 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-10.6 M | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
-44 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-4.04 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
-171 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
-18.8 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
-167 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
-214 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
1.61 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
-78.1 M | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
-93.4 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
4.38 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
232 M | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
14 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
-5.68 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
-155 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
-14 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
-241 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
-69.8 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Foghorn Therapeutics
FHTX
|
-83.1 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
71.8 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Sanofi
SNY
|
6.34 B | $ 41.77 | 0.41 % | $ 51 B | France |
 |
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Geron Corporation
GERN
|
-68.1 M | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-4.55 M | - | -3.76 % | $ 3.47 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-9.76 M | - | 3.16 % | $ 1.9 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-103 M | $ 1.14 | -2.56 % | $ 61.2 M | USA |
 |
Heron Therapeutics
HRTX
|
-224 K | $ 0.3 | -0.46 % | $ 50 M | USA |
 |
Achieve Life Sciences
ACHV
|
228 K | $ 6.55 | 0.85 % | $ 286 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-150 M | - | - | $ 58.1 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
52.7 M | $ 17.02 | 0.98 % | $ 2.29 B | Canada |
 |
iBio
IBIO
|
-34.6 M | $ 0.71 | -1.28 % | $ 73.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
4.43 M | $ 10.21 | -0.37 % | $ 92.2 M | USA |